Denmark backs generic lung drug in threat to GSK sales

LONDON (Reuters) - Denmark has approved the sale of an inhaled lung drug that analysts think is a generic copy of GlaxoSmithKline's $8 billion-a-year blockbuster Advair, threatening its future sales.

Source: Reuters: Health - December 18, 2013 Category: Consumer Health News Tags: healthNews Source Type: news